comparemela.com
Home
Live Updates
Zuma 12 - Breaking News
Pages:
Latest Breaking News On - Zuma 12 - Page 1 : comparemela.com
Diffuse Large B-Cell Lymphoma: Moving Novel Therapy to the Frontline Setting
Expert perspectives on recent efforts to move novel therapy from the relapsed/refractory to frontline setting of diffuse large B-cell lymphoma.
Translating recent evidence
Real world management
Refractory diffuse largeb cell lymphoma
Largeb cell lymphoma
Moving novel therapy
Diffuse largeb cell lymphoma
Relapsed refractory dlbcl
Rr dlbcl
L mind study
L mind trial
Tl mind
R chop
Front mind
Front mind study
Front mind trial
Zuma 7
ZUMA-23: A Global, Phase 3, Randomized Controlled Study of Axicabtagene Ciloleucel Versus Standard-of-Care as First-Line Therapy in Patients With High-Risk Large B-Cell Lymphoma
Jason R. Westin, MD, MS, FACP, reviews the background and study design of ZUMA-23, the first Phase III, randomized controlled study to evaluate CAR T-cell therapy as a first-line regimen in patients with high-risk LBCL.
Jasonr westin
Randomized controlled study
Axicabtagene ciloleucel versus standard of care
First line therapy
Patients with high risk largeb cell
Zuma 23
Zuma 23 study
Axicabtagene ciloleucel
Standard of care largeb cell lymphoma
Largeb cell lymphoma
High risk largeb cell lymphoma
First line treatments high risk largeb cell lymphoma
Zuma 7
Zuma 1
Zuma 12
Axi cel
vimarsana © 2020. All Rights Reserved.